HY-50® Vet delivers a high dose of Sodium hyaluronate in a small volume. Intra-articularly administered, HY-50® Vet alleviates aseptic joint inflammation and enhances joint function.

No more lame excuses!

With the launch of HY-50® Vet, Veterinary surgeons can turn to a new high dose, low volume injection for the successful treatment of equine non-infectious joint inflammation. Already a leading product in Scandinavia, the USA, Canada and Italy, HY-50® Vet is now available in the United Kingdom.

Delivering the highest dose of Sodium hyaluronate per ml of all the products currently on the market, HY-50®’s manufacturing method produces a highly effective and easy to use injection, free from animal origin proteins and, therefore, presenting minimal opportunity for adverse local reaction. In more than 500,000 doses sold worldwide, there has never been a report of a post treatment flare.

Indicated for the alleviation of joint inflammation and enhancement of joint function, HY-50® is presented in a pre-loaded syringe, delivering 50mg of Sodium hyaluronate per 3ml; all competitive products give just 20mg.

With some of the world’s finest competition horses in the UK, it is important that veterinary surgeons have HY-50® available to them. HY-50®’s high molecular weight, coupled with its unique fermentation and purification processes make it the product of choice.

HY50® Vet contains 50mg of HA in a 3ml fill volume
syringe: 250% more HA than any other product.

Click the below image to enlarge

Sodium Hyaluronate (Ph. Eur.) 50 mg/3 mL.
Sterile Solution for Injection.
For Animal Treatment.
For Intra-Articular Use in Horses
Composition: HY-50® Vet is a highly purified, sterile, non-pyrogenic, colourless aqueous solution of sodium hyaluronate derived by a bacterial fermentation process.
Each mL contains:
Active Ingredient:
Sodium Hyaluronate (Ph. Eur.) 17 mg
Inactive Ingredients:
Sodium Chloride (Ph. Eur.) 7.57 mg
Disodium Phosphate
Heptahydrate (Ph. Eur.) 3.78 mg
Sodium Dihydrogen Phosphate
Monohydrate (Ph. Eur.) 0.45 mg
Water for Injection (Ph. Eur.) q.s. to 1 mL
Pharmacodynamic Properties: Sodium hyaluronate is the sodium salt of hyaluronic acid, a non-sulphated acid mucopolysaccharide or glycosaminoglycan of high molecular weight composed of equimolar amounts of D glucuronic acid and N-acetylglucosamine linked together
by glycosidic bonds. The sodium hyaluronate in HY-50® Vet is produced by a bacterial fermentation process. Hyaluronic acid is a natural constituent of connective tissues in all mammals and its chemical structure is the same in all species. Vitreous humour, umbilical cord and synovial fluid are especially rich in hyaluronic acid. Hyaluronic acid is also found in the articular cartilage matrix. Hyaluronic acid has biochemical activities which are distinct from its physical and rheological properties. It is an effective free radical scavenger, a potent inhibitor of leucocyte and macrophage migration and aggregation, and enhances healing of connective tissue. Intra-articularly administered sodium hyaluronate alleviates aseptic joint inflammation and enhances joint function. The mechanism of action involved in the beneficial effects of sodium hyaluronate are not fully understood.
Pharmacokinetic Properties: Studies with radiolabelled hyaluronic acid in rabbit and sheep indicate that after intra-articular injection, hyaluronic acid is cleared from the joint within 4 to 5 days. Uptake is primarily via the lymphatics. Hyaluronate is metabolised in the liver.
Indications: For intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis.
Contraindications: Do not use in cases of joint infection.
Undesirable Effects: Transient mild swelling and/or heat has been reported in treated joints (2.7%). These self limiting local signs resolve spontaneously within 48 hours, and do not negate a successful therapeutic outcome.
Dosage and Administration: For single intra-articular injection: 3 mL (50 mg or 1 syringe) for carpal, fetlock and tibiotarsal joints. Smaller joints such as the intertarsal, tarsometatarsal and interphalangeal joints can be treated with 1.5 mL (25 mg). More than one joint may be treated at the same time. Excess synovial fluid should be removed whenever possible prior to injection. Remove product from refrigerator approximately 10 minutes before performing intra-articular injection. The injection should be administered under strict aseptic conditions. Ensure removal of dirt, hair, topical medicaments and soap/antiseptic residues. Intra-articular injections should not be made through overlying skin that is infected, blistered, scurfed or otherwise compromised. A sterile dressing and clean bandage should be applied after injection, as appropriate for the particular joint treated.
Special Precautions for Use: Radiographic evaluation should be carried out in cases of acute, severe lameness to ensure that the joints are free from serious fractures. Withdrawal Period: Meat and offal - zero days.
Storage Conditions: Store at 2° C-8° C. Do not freeze. Keep out of the reach of children.
Shelf-Life: Two (2) years. Single dose syringes made ready for injection shall be used immediately. Any unused portion of a syringe is to be discarded. Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
How Supplied: HY-50® Vet is supplied in 3 mL single-dose glass syringes, with each syringe packaged in an individual heat-sealed tray and carton.
Legal Category: POM-V
Registration Holder: Vet Medic Oy Fiskarsgatan 7c FIN-20750 Åbo FINLAND
Manufacturing Site: Lifecore Biomedical, Inc. 3515 Lyman Blvd. Chaska, Minnesota, U.S.A. 55318
Marketing Authorisation Number: Vm 19785/4000